https://www.fiercepharma.com/pharma/m-a-large-biotech-pharma-companies-will-have-1-7t-firepower-for-dealmaking-2022
Based on the companies’ cash positions and potential room to take on new debt, Porges said the 18 biopharma majors will have $1.72 trillion in M&A capacity. J&J topped the list with more than $200 billion in M&A firepower. Pfizer and Novartis followed with $175 billion and $154 billion, respectively. AbbVie, GSK, Bristol Myers Squibb and Merck will each boast more than $100 billion in firepower, the team figures.
J&J Partnership, page-357
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
42.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $89.07M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 42.5¢ | 42.0¢ | $21.21K | 50.38K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 20577 | 42.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 4662 | 1 |
View Market Depth
| Last trade - 13.09pm 01/10/2024 (20 minute delay) ? |
| OCC (ASX) Chart |